ALPK2 Antibody

What is ALPK2 and what are its primary physiological functions?

ALPK2 (Alpha-protein kinase 2, also known as HAK or Heart alpha-protein kinase) is an atypical protein kinase that recognizes phosphorylation sites where surrounding peptides have an alpha-helical conformation . This cardiac-specific atypical kinase plays crucial roles in:

• Cardiac development and cardiomyocyte differentiation

• Negative regulation of Wnt/beta-catenin signaling

• Prevention of cardiac diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF)

• Phosphorylation of tropomyosin 1 (TPM1), a key regulator that binds myosin to actin

Recent research has identified ALPK2 as a potential therapeutic target for cardiac diastolic dysfunction in HFpEF and age-related cardiac impairments, highlighting its physiological significance in cardiac function .

What applications are ALPK2 antibodies validated for in research protocols?

ALPK2 antibodies have been validated for multiple applications in research settings, with varying levels of optimization depending on the specific antibody. The primary applications include:

• Western blotting (WB): Detecting ALPK2 protein expression in tissue lysates with bands typically appearing at 210-237 kDa

• Immunohistochemistry (IHC): Analyzing ALPK2 localization in paraffin-embedded tissue sections, particularly in cardiac tissues

• ELISA: Quantitative detection of ALPK2 protein levels with high sensitivity

When selecting an ALPK2 antibody, researchers should verify that the specific antibody has been validated for their intended application, as not all antibodies perform optimally across all methodologies.

What is the optimal sample preparation protocol for detecting ALPK2 in cardiac tissue?

For optimal detection of ALPK2 in cardiac tissue samples:

• Tissue fixation and processing:

  • For IHC: Fix tissues in 10% neutral buffered formalin for 24-48 hours, followed by paraffin embedding

  • For Western blot: Flash-freeze fresh tissue in liquid nitrogen and store at -80°C until homogenization

• Protein extraction for Western blot:

  • Homogenize tissue in RIPA buffer supplemented with protease and phosphatase inhibitors

  • Use low-speed centrifugation (1000-3000 g) initially to remove debris while retaining large protein complexes

  • Employ sonication cautiously as ALPK2 is a large protein (210-237 kDa) susceptible to degradation

• Antigen retrieval for IHC:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective

  • Extend retrieval time to 20-30 minutes due to ALPK2's complex structure and potential masking in cardiac tissue

Validation through appropriate negative controls (pre-immune serum, antibody pre-incubation with immunizing peptide) is essential to confirm specific ALPK2 detection .

How does ALPK2 prevent cardiac diastolic dysfunction in heart failure models?

ALPK2 plays a critical role in preventing cardiac diastolic dysfunction through several molecular mechanisms:

• Tropomyosin phosphorylation: ALPK2 increases the phosphorylation of tropomyosin 1 (TPM1), a major regulator that binds myosin to actin, thereby influencing sarcomere relaxation dynamics

• Impact on cardiac stiffness: Studies using Alpk2-overexpressing mice demonstrated that enhanced ALPK2 expression mitigates cardiac stiffness in heart failure with preserved ejection fraction (HFpEF) models

• Age-related cardioprotection: Cardiomyocyte-specific Alpk2 deficiency exacerbates cardiac diastolic dysfunction induced by aging, suggesting ALPK2 maintains diastolic function during normal aging processes

Importantly, research using tamoxifen-inducible, cardiomyocyte-specific Alpk2-knockout mice revealed that while Alpk2 deficiency did not affect cardiac systolic dysfunction in myocardial infarction or pressure-overload-induced heart failure models, it specifically worsened diastolic parameters. This indicates ALPK2's specialized role in diastolic rather than systolic cardiac function .

What experimental approaches are recommended for investigating ALPK2's role in Wnt/beta-catenin signaling?

To effectively investigate ALPK2's role in Wnt/beta-catenin signaling, researchers should employ these methodological approaches:

• Genetic manipulation models:

  • Generate conditional knockout models using tamoxifen-inducible Cre-loxP systems (e.g., αMHC–CreERT2 positive mice crossed with Alpk2 flox/flox mice)

  • Develop overexpression models using CAG-Alpk2 expression vectors for gain-of-function studies

  • Implement CRISPR/Cas9 editing for precise modification of ALPK2 regulatory domains

• Signaling pathway analysis:

  • TOPFlash/FOPFlash reporter assays to quantify β-catenin-mediated transcriptional activity

  • Immunoprecipitation to identify physical interactions between ALPK2 and Wnt pathway components

  • Phosphorylation assays to determine if ALPK2 directly phosphorylates Wnt signaling components

• Transcriptional profiling:

  • RNA-seq analysis comparing wild-type and ALPK2-deficient cells to identify Wnt target genes affected by ALPK2

  • ChIP-seq to map β-catenin binding sites affected by ALPK2 manipulation

When designing these experiments, careful temporal control of ALPK2 manipulation is crucial, as its effects on Wnt signaling may be developmental stage-specific or context-dependent.

What is the relationship between oncogenic KRAS and ALPK2 expression in cancer models?

Research has revealed a complex relationship between oncogenic KRAS and ALPK2 expression in cancer models, particularly in colorectal cancer:

• Downregulation by oncogenic KRAS: In human colon cancer HCT116 cells, oncogenic KRAS significantly downregulates ALPK2 at both mRNA and protein levels. Quantitative RT-PCR demonstrated:

  • In 2D culture: ALPK2 expression was lower by 2364-fold in HCT116 cells (with oncogenic KRAS) compared to HKe3 cells (KRAS-disrupted)

  • In 3D culture: ALPK2 expression was lower by 1485-fold in HCT116 cells compared to HKe3 cells

• Functional implications in cancer biology:

  • Reduction in ALPK2 expression by ALPK2-specific siRNA inhibited apoptosis of HKe3 cells in 3D culture

  • This suggests ALPK2 may function as a tumor suppressor in certain contexts, as inhibition of apoptosis and genetic instability are hallmarks of pre-cancerous adenomas and early-stage colorectal cancer development

• Beyond KRAS mutations: Human colon cancer cell lines without KRAS mutations also exhibited reduced ALPK2 mRNA expression, indicating that other specific factors besides KRAS mutations can affect ALPK2 expression

These findings suggest ALPK2 may play a critical role in cancer biology, potentially through regulation of apoptotic pathways, with implications for understanding colorectal cancer progression and developing targeted therapies.

What are the critical validation steps for confirming ALPK2 antibody specificity?

Rigorous validation of ALPK2 antibody specificity is essential for generating reliable research data. Implement these critical validation steps:

• Positive and negative controls:

  • Positive control: Test antibody on cells transiently expressing tagged ALPK2 (e.g., HA-tagged ALPK2)

  • Negative control: Compare with antibody reactivity after pre-incubation with the immunizing peptide

  • Genetic knockdown: Validate using siRNA-mediated ALPK2 knockdown to demonstrate reduction in signal intensity

• Band size verification:

  • Confirm detection of the expected molecular weight band (210-237 kDa) in Western blot

  • Be aware that post-translational modifications may alter apparent molecular weight

• Cross-reactivity assessment:

  • Test antibody reactivity against related alpha kinase family members

  • Evaluate performance across species if cross-reactivity is claimed

• Application-specific validation:

  • For IHC: Include isotype controls and perform peptide competition assays

  • For Western blot: Confirm signal reduction in ALPK2 knockdown samples

  • For ELISA: Establish standard curves using recombinant ALPK2 protein

The research by Ito et al. demonstrated effective validation by showing that a 220-kDa band was strongly detected in cells expressing HA-tagged ALPK2, and significantly decreased in cells treated with ALPK2-specific siRNAs compared to controls .

What are the optimal Western blot conditions for detecting ALPK2 protein?

Detecting ALPK2 protein via Western blot requires specific optimization due to its high molecular weight (210-237 kDa) and potentially low expression levels in some tissues:

• Sample preparation and electrophoresis:

  • Use fresh samples whenever possible to minimize protein degradation

  • Incorporate additional protease inhibitors in lysis buffer

  • Employ 4-8% gradient gels for better resolution of high molecular weight proteins

  • Extend electrophoresis time at lower voltage (80-100V) to improve separation

• Transfer conditions:

  • Use wet transfer at 30V overnight (16-18 hours) at 4°C for effective transfer of large proteins

  • Consider adding 0.05% SDS to transfer buffer to facilitate large protein migration

  • Verify transfer efficiency with reversible protein staining before blocking

• Antibody conditions and detection:

  • Primary antibody dilution: 1:500 for Western blot applications

  • Extended incubation: Overnight at 4°C with gentle agitation

  • Consider signal enhancers for low-abundance detection

  • Use high-sensitivity chemiluminescent substrates with longer exposure times

• Controls and troubleshooting:

  • Include human fetal liver lysate as a positive control

  • Implement loading controls appropriate for high molecular weight proteins

  • If detecting multiple non-specific bands, increase blocking time and washing steps

Following these optimized conditions should yield detection of ALPK2 at the predicted band size of 210-237 kDa, as demonstrated in published research .

How should researchers design experiments to study ALPK2's effect on cardiac function in animal models?

Designing robust experiments to study ALPK2's effects on cardiac function requires careful consideration of animal models, functional assessments, and molecular analyses:

• Genetic model development:

  • Inducible cardiomyocyte-specific models: Generate tamoxifen-inducible, cardiomyocyte-specific Alpk2-knockout mice (e.g., using αMHC–CreERT2 × Alpk2 flox/flox) to control timing of ALPK2 deletion

  • Overexpression models: Develop CAG-Alpk2-overexpressing mice to assess gain-of-function effects

  • Conventional knockout: Consider whole-body knockout using CRISPR/Cas9 for developmental studies

• Experimental disease models:

  • HFpEF model: Implement aging-induced or comorbidity-based models (hypertension, metabolic syndrome)

  • Pressure overload: Use transverse aortic constriction (TAC)

  • Myocardial infarction: Perform left anterior descending coronary artery ligation

  • Aging studies: Follow animals through natural aging processes (12-24 months)

• Functional assessments:

  • Echocardiography: Measure both systolic (ejection fraction, fractional shortening) and diastolic parameters (E/A ratio, deceleration time, E/e' ratio)

  • Pressure-volume loops: Obtain load-independent measures of diastolic function

  • Exercise capacity: Assess functional impact through exercise testing

• Molecular and cellular analyses:

  • Phosphorylation studies: Measure tropomyosin 1 phosphorylation status using phospho-specific antibodies

  • Histology and immunohistochemistry: Assess cardiac remodeling and ALPK2 localization

  • Cardiomyocyte isolation: Perform functional studies in isolated cells to assess contractility and calcium handling

This comprehensive approach, as exemplified in recent studies, allows for detailed characterization of ALPK2's specific role in cardiac function, particularly its preferential effects on diastolic rather than systolic function .

What are the potential therapeutic applications of targeting ALPK2 in heart failure with preserved ejection fraction?

Recent research suggests several promising therapeutic applications for targeting ALPK2 in heart failure with preserved ejection fraction (HFpEF):

• Enhancing ALPK2 activity: Overexpression of ALPK2 has been shown to increase phosphorylation of tropomyosin 1 and mitigate cardiac stiffness in HFpEF models, suggesting that pharmacological enhancement of ALPK2 activity could offer therapeutic benefits

• Age-related cardiac protection: Since cardiomyocyte-specific Alpk2 deficiency exacerbates cardiac diastolic dysfunction induced by aging, ALPK2-targeted therapies may be particularly beneficial for elderly patients with HFpEF

• Targeted delivery approaches:

  • Cardiomyocyte-specific gene therapy to increase ALPK2 expression

  • Small molecule activators of ALPK2 kinase activity

  • miRNA-based approaches to upregulate endogenous ALPK2 expression

• Combination therapies: ALPK2-targeted interventions could potentially be combined with established HFpEF treatments addressing contributing comorbidities (hypertension, diabetes)

The specificity of ALPK2 for cardiac diastolic function, rather than systolic function, makes it an attractive target for HFpEF, a condition characterized primarily by diastolic dysfunction for which few effective therapies currently exist .

How does ALPK2's role in colorectal cancer suggest new avenues for cancer research?

The emerging understanding of ALPK2's involvement in colorectal cancer biology opens several novel research directions:

• Tumor suppressor potential: The finding that ALPK2 reduction inhibits apoptosis in colorectal cancer models suggests it may function as a tumor suppressor, warranting investigation into:

  • ALPK2 expression patterns across cancer stages and correlation with patient outcomes

  • Mechanisms by which ALPK2 regulates apoptotic pathways in cancer cells

  • Potential for ALPK2 restoration as a therapeutic strategy

• KRAS-ALPK2 signaling axis:

  • The dramatic downregulation of ALPK2 by oncogenic KRAS (2364-fold in 2D culture) suggests ALPK2 may be a key downstream effector in KRAS-driven oncogenesis

  • This presents opportunities to bypass KRAS (historically challenging to target) by instead targeting ALPK2 pathways

• 3D culture significance:

  • The differential expression of ALPK2 in 2D versus 3D cultures highlights the importance of studying this kinase in physiologically relevant models

  • This suggests 3D organoid models may be particularly valuable for studying ALPK2's role in cancer biology

• Beyond KRAS mutations:

  • The observation that ALPK2 expression is reduced even in cell lines without KRAS mutations indicates alternative regulatory mechanisms that deserve investigation

  • This may reveal new signaling pathways involved in colorectal cancer development

These findings collectively suggest ALPK2 may be a critical node in cancer signaling networks, potentially offering new diagnostic, prognostic, and therapeutic opportunities for colorectal cancer research.

What are the recommended approaches for investigating ALPK2 substrates and kinase activity?

Investigating ALPK2 substrates and characterizing its kinase activity requires specialized approaches due to its atypical kinase classification:

• Substrate identification strategies:

  • Phosphoproteomic analysis: Compare phosphorylation profiles between wild-type and ALPK2-deficient samples using mass spectrometry

  • Consensus motif determination: Analyze known substrates like tropomyosin 1 to identify potential recognition motifs

  • Protein array screening: Test recombinant ALPK2 against protein arrays to identify potential substrates

  • Bioinformatic prediction: Search for proteins with alpha-helical regions surrounding potential phosphorylation sites

• In vitro kinase assays:

  • Recombinant protein production: Express full-length or catalytic domain of ALPK2 in appropriate expression systems

  • Activity assays: Measure phosphorylation of validated substrates (e.g., tropomyosin 1) using:

    • Radiolabeled ATP incorporation

    • Phospho-specific antibodies

    • Mass spectrometry-based quantification

  • Inhibitor screening: Test potential small molecule modulators of ALPK2 activity

• Structural studies:

  • Domain mapping: Identify critical regions for kinase activity and substrate recognition

  • Structural prediction: Generate models based on related alpha-kinases

  • X-ray crystallography or cryo-EM: Determine ALPK2 structure, particularly in complex with substrates

• Cellular validation:

  • Phospho-specific antibodies: Develop and validate antibodies against phosphorylated ALPK2 substrates (like phospho-TPM1)

  • Phospho-mutant expression: Create phospho-null and phospho-mimetic mutants of putative substrates to assess functional consequences

These approaches, particularly when combined, can provide comprehensive insights into ALPK2's substrate specificity and the functional consequences of its kinase activity in both cardiac and cancer contexts.

How do different commercially available ALPK2 antibodies compare in research applications?

Researchers should consider these key differences when selecting ALPK2 antibodies for specific applications:

Performance considerations:

• Application-specific performance:

  • For Western blot: Abcam's ab111909 has demonstrated specific detection at the expected molecular weight in human samples

  • For IHC: Antibodies.com's A100696 has been validated in human heart tissue with appropriate controls

• Reliability factors:

  • Citation record: Consider antibodies cited in peer-reviewed publications

  • Validation data: Evaluate available validation data for your specific application

  • Lot-to-lot consistency: Request information on quality control measures

• Troubleshooting guidance:

  • For weak signals: Consider longer incubation times or higher antibody concentrations

  • For multiple bands: Increase blocking time or try different blocking agents

  • For background issues: Optimize washing steps and consider alternative secondary antibodies

When possible, validate multiple antibodies in your specific experimental system to determine optimal performance for your research goals.

What are common challenges when studying ALPK2 and how can they be overcome?

Researchers studying ALPK2 face several technical challenges that can be addressed through strategic methodological approaches:

• High molecular weight detection issues:

  • Challenge: ALPK2's large size (210-237 kDa) complicates detection via Western blot

  • Solution: Use low percentage gels (4-8%), extended transfer times at low voltage, and specialized transfer buffers containing SDS to facilitate migration of large proteins

• Low endogenous expression levels:

  • Challenge: ALPK2 may be expressed at low levels in certain tissues or conditions

  • Solution: Employ signal enhancement techniques, concentrate protein samples, and use high-sensitivity detection systems; consider enrichment approaches prior to analysis

• Functional redundancy with other kinases:

  • Challenge: Other kinases may compensate for ALPK2 loss in knockout models

  • Solution: Implement acute knockdown strategies (inducible systems), analyze early timepoints after deletion, and consider double-knockout approaches with related kinases

• Context-dependent effects:

  • Challenge: ALPK2's effects may vary significantly between 2D and 3D cultures or in different disease models

  • Solution: Evaluate ALPK2 function across multiple model systems, including 2D cultures, 3D organoids, and in vivo models to comprehensively characterize its role

• Variability in cancer models:

  • Challenge: ALPK2 expression changes in cancer may depend on specific genetic backgrounds beyond KRAS mutations

  • Solution: Analyze ALPK2 across diverse cancer cell lines with well-characterized genetic profiles and validate findings in patient-derived samples

By anticipating these challenges and implementing appropriate methodological strategies, researchers can generate more reliable and reproducible data on ALPK2 function in both cardiac and cancer contexts.

How should researchers interpret conflicting data regarding ALPK2 function across different experimental systems?

When confronting contradictory findings regarding ALPK2 function, researchers should employ these systematic approaches for data interpretation:

• Contextual analysis framework:

  • Model system differences: Evaluate whether discrepancies arise from differences in:

    • 2D versus 3D culture systems (demonstrated to affect ALPK2 expression by 1485-fold in HCT116 cells)

    • Cell lines versus primary cells or in vivo models

    • Acute versus chronic ALPK2 manipulation

  • Tissue-specific functions: Consider that ALPK2 may have distinct roles in cardiac tissue versus other tissues

• Genetic background considerations:

  • Mutation status: Assess whether KRAS mutation status or other genetic factors might explain divergent findings

  • Species differences: Evaluate whether findings in mouse models translate to human systems

  • Developmental timing: Consider whether ALPK2's function varies across developmental stages

• Methodological reconciliation strategies:

  • Direct comparison experiments: Design experiments that directly compare different systems under identical conditions

  • Dose-dependency analysis: Determine whether ALPK2 exhibits threshold effects or biphasic responses

  • Temporal analysis: Examine whether apparent contradictions reflect different timepoints in a dynamic process

• Integrative approaches:

  • Multi-omics integration: Combine transcriptomic, proteomic, and phosphoproteomic data to build comprehensive models of ALPK2 function

  • Network analysis: Place contradictory findings in the context of broader signaling networks

  • Systematic review methodology: Apply formal meta-analysis techniques to quantitatively assess conflicting literature

By applying these interpretive frameworks, researchers can transform apparent contradictions into deeper insights about the context-dependent functions of ALPK2 in both physiological and pathological settings.